ABL Diagnostics obtained CE-IVD registration for molecular tests covering HIV-1, respiratory pathogens, and viral meningitis, expanding its portfolio in Europe. The company described updated PCR-based genotyping via DeepChek Whole Genome HIV-1 Genotyping v1.2, plus multiplex assays for respiratory pathogens and viral meningitis targets in blood and cerebrospinal fluid specimens. ABL also amended an equity line and share loan agreement with major stockowners, adding operational safeguards such as minimum floor pricing and reduced future drawdown sizes.